Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Y-mAbs Therapeutics (NASDAQ:YMAB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

YMAB has been the topic of a number of other research reports. Cowen reiterated a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Protalix Biotherapeutics in a research note on Monday, June 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $30.80.

YMAB opened at $22.95 on Friday. Y-mAbs Therapeutics has a one year low of $15.17 and a one year high of $31.00. The stock has a market cap of $782.01 million and a P/E ratio of -15.30. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 0.02. The firm has a 50-day simple moving average of $21.93.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.07). Analysts forecast that Y-mAbs Therapeutics will post -1.95 EPS for the current year.

In related news, insider Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $22.40, for a total transaction of $89,600.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 28,000 shares of company stock worth $592,880 in the last 90 days. 38.40% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its holdings in Y-mAbs Therapeutics by 2,178.9% during the fourth quarter. BlackRock Inc. now owns 341,831 shares of the company’s stock valued at $6,952,000 after purchasing an additional 326,831 shares in the last quarter. Citigroup Inc. acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $37,000. Northern Trust Corp acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,533,000. Geode Capital Management LLC acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,587,000. Finally, American International Group Inc. acquired a new stake in Y-mAbs Therapeutics during the fourth quarter valued at approximately $93,000. Hedge funds and other institutional investors own 24.80% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Strategic Wealth Partners Ltd. Sells 294 Shares of FirstEnergy Corp.
Strategic Wealth Partners Ltd. Sells 294 Shares of FirstEnergy Corp.
Vanguard Real Estate ETF  Shares Sold by Strategic Wealth Partners Ltd.
Vanguard Real Estate ETF Shares Sold by Strategic Wealth Partners Ltd.
SPDR Portfolio Long Term Treasury ETF  Shares Sold by Strategic Wealth Partners Ltd.
SPDR Portfolio Long Term Treasury ETF Shares Sold by Strategic Wealth Partners Ltd.
Strategic Wealth Partners Ltd. Sells 2,592 Shares of ISHARES TR/CORE U S REIT ETF
Strategic Wealth Partners Ltd. Sells 2,592 Shares of ISHARES TR/CORE U S REIT ETF
Strategic Wealth Partners Ltd. Lowers Stock Holdings in Diageo plc
Strategic Wealth Partners Ltd. Lowers Stock Holdings in Diageo plc
Strategic Wealth Partners Ltd. Sells 11,768 Shares of iShares US Real Estate ETF
Strategic Wealth Partners Ltd. Sells 11,768 Shares of iShares US Real Estate ETF


© 2006-2019 Ticker Report